MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

Proceeds from maturitiesof investment...$27,500K (-82.17%↓ Y/Y)Issuance of common stockthrough employee stock...$464K (28.53%↑ Y/Y)Proceeds from theexercise of stock options$141K (513.04%↑ Y/Y)Net cash provided byinvesting activities$15,056K (-46.20%↓ Y/Y)Net cash provided byfinancing activities$605K (57.55%↑ Y/Y)Canceled cashflow$12,444K Net decrease in cashand cash...$137K (104.79%↑ Y/Y)Canceled cashflow$15,524K Purchases of investmentsecurities$12,423K (-90.15%↓ Y/Y)Purchases of property andequipment$21K (-86.79%↓ Y/Y)Stock-based compensation$3,867K (-48.60%↓ Y/Y)Accounts payable andother liabilities$955K (296.27%↑ Y/Y)Depreciation$151K (-51.45%↓ Y/Y)Non-cash lease expense$74K (1333.33%↑ Y/Y)Net cash used inoperating activities-$15,524K (50.29%↑ Y/Y)Canceled cashflow$5,047K Net loss-$20,165K (45.20%↑ Y/Y)Prepaid expense andother assets$391K (-59.06%↓ Y/Y)Amortization of premiums oninvestment securities, net$15K (-99.24%↓ Y/Y)
Cash Flow

Design Therapeutics, Inc. (DSGN)

Design Therapeutics, Inc. (DSGN)

source: myfinsight.com